OS Therapies, Inc. (OSTX)
1.77
+0.03
(+1.72%)
USD |
NYAM |
Sep 22, 16:00
1.79
+0.02
(+1.13%)
After-Hours: 20:00
OS Therapies Enterprise Value : 81.02M for Sept. 22, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 22, 2026 | 81.02M |
| September 21, 2026 | 79.66M |
| September 18, 2026 | 81.02M |
| September 17, 2026 | 83.73M |
| September 16, 2026 | 80.11M |
| September 15, 2026 | 81.47M |
| September 14, 2026 | 77.85M |
| September 11, 2026 | 76.94M |
| September 10, 2026 | 83.28M |
| September 09, 2026 | 85.09M |
| September 08, 2026 | 83.73M |
| September 04, 2026 | 86.00M |
| September 03, 2026 | 83.28M |
| September 02, 2026 | 78.30M |
| September 01, 2026 | 76.04M |
| August 31, 2026 | 77.39M |
| August 28, 2026 | 75.13M |
| August 27, 2026 | 76.94M |
| August 26, 2026 | 75.58M |
| August 25, 2026 | 75.58M |
| August 24, 2026 | 71.05M |
| August 21, 2026 | 72.87M |
| August 20, 2026 | 72.41M |
| August 19, 2026 | 66.98M |
| August 18, 2026 | 66.07M |
| Date | Value |
|---|---|
| August 17, 2026 | 67.43M |
| August 14, 2026 | 74.22M |
| August 13, 2026 | 73.32M |
| August 12, 2026 | 73.77M |
| August 11, 2026 | 73.32M |
| August 10, 2026 | 74.68M |
| August 07, 2026 | 73.32M |
| August 06, 2026 | 74.68M |
| August 05, 2026 | 73.32M |
| August 04, 2026 | 74.68M |
| August 03, 2026 | 71.05M |
| July 31, 2026 | 69.70M |
| July 30, 2026 | 71.51M |
| July 29, 2026 | 67.88M |
| July 28, 2026 | 68.79M |
| July 27, 2026 | 70.15M |
| July 24, 2026 | 69.70M |
| July 23, 2026 | 71.51M |
| July 22, 2026 | 71.05M |
| July 21, 2026 | 71.51M |
| July 20, 2026 | 69.24M |
| July 17, 2026 | 70.15M |
| July 16, 2026 | 68.79M |
| July 15, 2026 | 71.05M |
| July 14, 2026 | 76.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.663B |
| Alnylam Pharmaceuticals, Inc. | 33.33B |
| Anika Therapeutics, Inc. | 266.41M |
| Savara, Inc. | 945.99M |
| Vericel Corp. | 1.990B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.632M |
| Total Expenses (Quarterly) | 8.632M |
| EPS Diluted (Quarterly) | -0.1966 |
| Earnings Yield | -58.95% |
| Normalized Earnings Yield | -58.95 |